Pharmacokinetic, pharmacodynamic, and activity evaluation of TMX-101 in a multicenter phase 1 study in patients with papillary non-muscle-invasive bladder cancer

Clinical Genitourinary Cancer

Volumn 13, Issue 3, 2015, Pages 204-209.e2

  Arends, Tom J H ^a   Lammers, Rianne J M ^a   Falke, Johannes ^a   Van Der Heijden, Antoine G ^a   Rustighini, Irene ^c   Pozzi, Raffaella ^c   Ravic, Miroslav ^d   Eisenhardt, Andreas ^e   Vergunst, Henk ^b   Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c Telormedix SA   (Switzerland)

^d Pharma Integra Ltd   (United Kingdom)

^e Pur r Praxisklinik Urologie   (Germany)

Author keywords

Bladder cancer; Bladder instillation; Immunotherapy; Toll like receptor 7; Treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TMX 101; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; VASCULOTROPIN; AMINOQUINOLINE DERIVATIVE; IMIQUIMOD;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLADDER DISCOMFORT; CANCER FATIGUE; CANCER PATIENT; CLINICAL ARTICLE; CYSTALGIA; CYSTOSCOPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INSTILLATION; DRUG URINE LEVEL; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NON MUSCLE INVASIVE BLADDER CANCER; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY URGENCY; CARCINOMA, RENAL CELL; CLINICAL TRIAL; INTRAVESICAL DRUG ADMINISTRATION; KIDNEY NEOPLASMS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; URINE;

ADMINISTRATION, INTRAVESICAL; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CYSTOSCOPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84929129765     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.12.010     Document Type: Article

References (26)

1. M.F. Botteman, C.L. Pashos, and A. Redaelli et al. The health economics of bladder cancer: a comprehensive review of the published literature Pharmacoeconomics 21 2003 1315 1330
2. R. Siegel, E. Ward, and O. Brawley et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 2011 212 236
3. M. Babjuk, M. Burger, and R. Zigeuner et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update, 2013 Eur Urol 64 2013 639 653
4. H. Kumar, T. Kawai, and S. Akira Toll-like receptors and innate immunity Biochem Biophys Res Commun 388 2009 621 625
5. J.K. Geisse, P. Rich, and A. Pandya et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study J Am Acad Dermatol 47 2002 390 398
6. E. Vacchelli, A. Eggermont, and C. Sautes-Fridman et al. Trial watch: Toll-like receptor agonists for cancer therapy Oncoimmunology 2 2013 e25238
7. E.B. Smith, M. Schwartz, and H. Kawamoto et al. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder J Urol 177 2007 2347 2351
8. J. Falke, R.J. Lammers, and H.C. Arentsen et al. Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer J Urol 189 2013 2077 2082
9. G.N. Thalmann, A. Sermier, and C. Rentsch et al. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guérin J Urol 164 2000 2129 2133
10. T. Seya, T. Akazawa, and J. Uehori et al. Role of Toll-like receptors and their adaptors in adjuvant immunotherapy for cancer Anticancer Res 23 2003 4369 4376
11. T. Hayashi, B. Crain, and M. Corr et al. Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer Int J Urol 17 2010 483 490
12. C.A. Dinarello Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 29 2010 317 329
13. Y. Carmi, E. Voronov, and S. Dotan et al. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis J Immunol 183 2009 4705 4714
14. X. Song, E. Voronov, and T. Dvorkin et al. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness J Immunol 171 2003 6448 6456
15. E. Voronov, D.S. Shouval, and Y. Krelin et al. IL-1 is required for tumor invasiveness and angiogenesis Proc Natl Acad Sci U S A 100 2003 2645 2650
16. F. Vidal-Vanaclocha, C. Amezaga, and A. Asumendi et al. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases Cancer Res 54 1994 2667 2672
17. P.K. Kopparapu, S.A. Boorjian, and B.D. Robinson et al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer Anticancer Res 33 2013 2381 2390
18. M. Reale, R. Intorno, and R. Tenaglia et al. Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guérin immunotherapy Cancer Immunol Immunother 51 2002 91 98
19. H. Yang, C. Kim, and M.J. Kim et al. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer Mol Cancer 10 2011 36
20. D. Goldstein, P. Hertzog, and E. Tomkinson et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification J Infect Dis 178 1998 858 861
21. I. Soria, P. Myhre, and V. Horton et al. Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose Int J Clin Pharmacol Ther 38 2000 476 481
22. B. Reizis, M. Colonna, and G. Trinchieri et al. Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system? Nat Rev Immunol 11 2011 558 565
23. E.J. Hennessy, A.E. Parker, and L.A. O'Neill Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 9 2010 293 307
24. B. Drobits, M. Holcmann, and N. Amberg et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells J Clin Invest 122 2012 575 585
25. H. Hemmi, T. Kaisho, and O. Takeuchi et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway Nat Immunol 3 2002 196 200
26. J. Falke, R.J. Lammers, and H.C. Arentsen et al. Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer J Urol 189 2013 2077 2082